

해외 바이오의약품 임상 현황 (2019.11.12~2019.11.18)

한국바이오의약품협회, 2019.11.19.
출처: ClinicalTrials.gov

○ 미국 13건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03735589	Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Stage II Fallopian Tube Cancer AJCC v8 Stage II Ovarian Cancer AJCC v8 Stage II Primary Peritoneal Cancer AJCC v8 Stage IIA Fallopian Tube Cancer AJCC v8 Stage IIA Ovarian Cancer AJCC v8 Stage IIA Primary Peritoneal Cancer AJCC v8 Stage IIB Fallopian Tube Cancer AJCC v8 Stage IIB Ovarian Cancer AJCC v8 Stage IIB Primary Peritoneal Cancer AJCC v8 Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8	Biological: Alpha-type-1 Polarized Dendritic Cells Biological: Autologous Natural Killer Cell-like CTLs	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04047810	Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease	Biological: Mesenchymal Stem Cells	Mayo Clinic	Phase 1
NCT03970096	Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia	Acute Biphenotypic Leukemia Acute Leukemia of Ambiguous Lineage Acute Lymphoblastic Leukemia in Remission Acute Myeloid Leukemia in Remission Acute Undifferentiated Leukemia Allogeneic Hematopoietic Stem Cell Transplantation Recipient Blastic Plasmacytoid Dendritic Cell Neoplasm Blasts Under 5 Percent of Bone Marrow Nucleated Cells Donor Lymphoblastic Lymphoma Mixed Phenotype Acute Leukemia	Radiation: Total-Body Irradiation Drug: Thiotepa Drug: Fludarabine Drug: Fludarabine Phosphate Drug: Tacrolimus Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs Drug: Methotrexate Biological: Anti-Thymocyte Globulin Drug: Cyclophosphamide Biological: Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells Drug: Peripheral Blood Stem Cell	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT03856099	TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab	Recurrent Glioblastoma	Drug: TTAC-0001	PharmAbcine	Phase 2
NCT04136834	A Phase I Open-label Study for Subjects With Advanced Malignancies	Advanced Solid Malignancies	Biological: PT01 (Pegtomarginase)	Athenex, Inc.	Phase 1
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage III Gastric Cancer AJCC v8 Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVA Gastric Cancer AJCC v8 Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVB Gastric Cancer AJCC v8 Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 High-Frequency Microsatellite Instability Locally Advanced Urothelial Carcinoma Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Head and Neck Squamous Cell Carcinoma Metastatic Lung Non-Small Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Melanoma Metastatic Pancreatic Adenocarcinoma Metastatic Urothelial Carcinoma Mismatch Repair Deficiency Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage III Gastric Cancer AJCC v8 Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIA Gastric Cancer AJCC v8 Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIB Gastric Cancer AJCC v8 Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIC Gastric Cancer AJCC v8 Pathologic Stage IV Cutaneous Melanoma AJCC v8 Pathologic Stage IV Gastric Cancer AJCC v8 Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 PD-L1 Positive Progressive Disease Recurrent Head and Neck Squamous Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Refractory Pancreatic Adenocarcinoma Stage II Pancreatic Cancer AJCC v8 Stage IIA Pancreatic Cancer AJCC v8 Stage IIB Pancreatic Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Unresectable Malignant Solid Neoplasm Unresectable Melanoma Unresectable Pancreatic Adenocarcinoma	Biological: Pembrolizumab Drug: Sonidegib	Mayo Clinic National Cancer Institute (NCI)	Phase 1
NCT03346135	Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma	Plasma Cell Myeloma Secondary Amyloidosis	Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Melphalan Biological: Daratumumab Other: Laboratory Biomarker Analysis	City of Hope Medical Center Janssen, LP	Phase 2
NCT04166773	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	Nonalcoholic Steatohepatitis	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 2

해외 바이오의약품 임상 현황 (2019.11.12~2019.11.18)

한국바이오의약품협회, 2019.11.19.
출처: ClinicalTrials.gov

NCT04152382	A Safety Study of LY3462817 in Participants With Psoriasis	Psoriasis	Drug: LY3462817 - IV Drug: LY3462817 - SC Drug: Placebo - IV Drug: Placebo - SC	Eli Lilly and Company	Phase 1
NCT04162015	A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma	Malignant Pleural Mesothelioma	Drug: Nivolumab Drug: Pemetrexed Drug: Cisplatin or Carboplatin	Memorial Sloan Kettering Cancer Center Bristol-Myers Squibb	Phase 1
NCT04108195	A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab Drug: JNJ-64407564 Drug: JNJ-64007957	Janssen Research & Development, LLC	Phase 1
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2

○ 영국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03946449	Assessment of Changes in a Novel Histological Activity Scale in Response to ARO-AAT	Alpha 1-Antitrypsin Deficiency	Drug: ARO-AAT Injection	Arrowhead Pharmaceuticals	Phase 2
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2
NCT04166773	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	Nonalcoholic Steatohepatitis	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 2

○ 프랑스 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03964792	Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the α AS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)	Sickle Cell Disease	Genetic: DREPAGLOBE drug product	Assistance Publique - H ^ô pital Pitaux de Paris	Phase 1 Phase 2
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2
NCT04166773	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	Nonalcoholic Steatohepatitis	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 2

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT03946449	Assessment of Changes in a Novel Histological Activity Scale in Response to ARO-AAT	Alpha 1-Antitrypsin Deficiency	Drug: ARO-AAT Injection	Arrowhead Pharmaceuticals	Phase 2

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2

○ 중국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04164745	Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer	NSCLC	Drug: Anlotinib, oral capsule Biological: Pembrolizumab	Peking Union Medical College Hospital	Phase 2
NCT04140318	Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma	Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma	Drug: sintilimab Drug: nab-paclitaxel	Chinese Academy of Medical Sciences Chinese PLA General Hospital Beijing Friendship Hospital Beijing Hospital	Phase 2
NCT04085289	A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants	Healthy	Drug: Galcanezumab Drug: Placebo	Eli Lilly and Company	Phase 1